Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone

Nephrology Dialysis Transplantation

Volumn 15, Issue 3, 2000, Pages 375-378

  Pańczyk Tomaszewska, Małgorzata ^a   Ziółkowska, Helena ^a   Dȩbiński, Andrzej ^b   Sieniawska, Maria ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL FOOD AND NUTRITION INSTITUTE   (Poland)

Author keywords

Alfacalcidol; Alkaline phosphatase; Children; End stage renal failure; Growth hormone; Growth retardation; Parathyroid hormone

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; HUMAN GROWTH HORMONE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DIALYSIS; GROWTH RETARDATION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0343776149     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.3.375     Document Type: Article

References (14)

1. Fine RN, Kohaut EC, Brown D, Perlman JA. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of multicenter randomised double-blind placebo-controlled study. J Pediatr 1994; 124: 374-382
2. Hokken-Koelega ACS, Stijnen T, De Jong MCJW et al. Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. J Clin Endocrinol Metab 1994; 79: 1185-1190
3. Mehls O, Broyer M. Growth response to recombinant human growth hormone in short prepubertal children with chronic renal failure with or without dialysis. Acta Paediatr Scand Suppl 1994; 399: 81-87
4. Berard E, Crosnier H, Six-Beneton A, Chevallier T, Cochat P, Broyer M. Recombinant human growth hormone treatment of children on hemodialysis. Pediatr Nephrol 1998; 12: 304-310
5. Feber J, Cochat P, Lebl J et al. Body composition in children receiving recombinant human growth hormone after renal transplantation. Kidney Int 1998; 54: 951-955
6. Sieniawska M, Pańczyk-Tomaszewska M, Ziółkowska H. The influence of growth hormone treatment on bone metabolism in dialysis patients. Br J Clin Pract [Suppl] 1996; 85: 61-63
7. Watkins SL. Bone disease in patients receiving growth hormone. Kidney Int [Suppl] 1996; 49: S126-127
8. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987; 2: 595-610
9. Jehle PM, Jehle DR, Mohan S, Keller F. Renal osteodystrophy: new insights in pathophysiology and treatment modalities with special emphasis on the insulin-like growth factor system. Nephron 1998; 79: 249-264
10. Huffer WE. Morphology and biochemistry of bone remodelling: possible control by vitamin D, parathyroid hormone and other substances. Lab Invest 1988; 59: 418-423
11. Fine RN, Yadin O, Moulton L et al. Five years' experience with recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr Endocrinol 1994; 7: 1-12
12. Hansen TB, Brixen K, Vahl N et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis and bone metabolism in adults with acquired GH deficiency: a double blind, randomised, placebo-controlled study. J Clin Endocrinol Metab 1996; 81: 3352-3359
13. Joffe P, Heaf JG, Jensen C. Can bone histomorphometry be predicted by clinical assessment and non invasive techniques in peritoneal dialysis. Miner Electrolyte Metab 1996; 22: 224-233
14. Kuizon BD, Goodman WG, Juppner H et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998; 53: 205-211